Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
2026 · 3rd Quarter (July 1 - Sep 30)
BC3 TECHNOLOGIES INC.
Filed by C2 STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 17, 2026
- Income
- $10,000.00
- Expenses
- Not reported
- Registrant
- C2 STRATEGIES
- Client
- BC3 TECHNOLOGIES INC.
- Filing UUID
- 2eeb611d-8635-484e-8f32-17bf26593cee
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
Federal support for fielding FDA cleared hemostatic wound care technology for military and first responder use. Matters relating to combat casualty care and prehospital hemorrhage control, including Department of Defense medical materiel and Defense Health Agency programs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.